Skip to main content
    P

    Protara Therapeutics Inc (TARA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.38
    -0.15 (-5.93%)

    Market Cap: $155.77M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Protara Therapeutics Inc (TARA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Protara Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$57.44M, operating cash flow was -$56.37M and free cash flow was -$56.46M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$21.69M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $64.55M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$42.63M$31.70M$24.99M$16.81M$21.09M$11.98M$3.88M$11.85M$21.69M$18.87M
    Operating income-$64.55M-$49.15M-$43.61M-$67.06M-$47.49M-$34.44M-$7.83M-$21.37M-$30.36M-$28.70M
    Net income-$57.44M-$44.60M-$40.42M-$65.95M-$47.25M-$33.98M-$7.83M-$20.73M-$29.96M-$28.53M
    EBITDAN/A-$49.12MN/A-$65.68M-$45.40M-$34.34M-$7.81M-$21.10M-$30.08M-$28.46M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$332.00K$0$0$0$1.21M
    Gross profit$0$0$0-$93.00K$0$0$0$166.00K$0$0$0$1.10M
    Operating income-$23.15M-$23.32M-$19.63M-$19.08M-$14.76M-$16.59M-$14.12M-$14.31M-$12.33M-$10.66M-$11.85M-$11.04M
    Net income-$21.69M-$21.67M-$17.78M-$17.31M-$13.26M-$14.96M-$11.91M-$12.77M-$11.22M-$9.51M-$11.10M-$10.22M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.24M by $48.41M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$209.47M$181.45M$78.95M$113.29M$172.60M$203.16M$1.22M$23.52M$43.98M$43.52M
    Current assets$159.50M$172.16M$68.70M$86.15M$93.11M$169.44M$764.00K$23.24M$43.48M$42.76M
    Cash and equivalents$49.66M$162.80M$39.59M$24.13M$35.72M$168.60M$564.00K$19.37M$21.17M$36.39M
    Total liabilities$13.06M$14.32M$10.63M$11.21M$10.68M$3.91M$3.35M$3.08M$9.24M$5.08M
    Short-term debt$1.24M$1.12M$983.00K$917.00K$855.00K$88.00KN/AN/A$20.00KN/A
    Shareholder equity$196.41M$167.13M$68.32M$102.08M$161.91M$199.24M-$2.13M$20.44M$34.74M$38.44M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$156.54M$176.09M$191.92M$209.47M$144.64M$156.93M$168.56M$181.45M$94.09M$101.65M$68.13M$78.95M
    Total liabilities$15.52M$14.78M$10.71M$13.06M$12.35M$12.51M$10.07M$14.32M$12.30M$9.60M$9.73M$10.63M
    Cash and equivalents$25.15M$17.08M$14.74M$49.66M$12.55M$31.50M$91.46M$162.80M$51.76M$89.58M$52.23M$39.59M
    Shareholder equity$141.02M$161.31M$181.21M$196.41M$132.29M$144.42M$158.48M$167.13M$81.79M$92.05M$58.41M$68.32M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$56.37M-$35.81M-$37.56M-$26.46M-$34.50M-$23.41M-$5.01M-$23.23M-$22.35M-$23.69M
    Capital expenditures$94.00K$63.00K$45.00K$120.00K$596.00K$884.00K$475.00K$119.00K$35.00K$271.00K
    Free cash flow-$56.46M-$35.87M-$37.60M-$26.58M-$35.10M-$24.29M-$5.49M-$23.35M-$22.39M-$23.96M
    Share repurchasesN/AN/AN/A$90.00K$228.00K$0N/AN/AN/AN/A
    Investing cash flow-$139.49M$19.16M$53.11M$14.95M-$98.19M$2.83M-$475.00K$18.43M-$16.10M$19.92M
    Financing cash flow$82.72M$139.87M-$91.00K-$90.00K-$228.00K$189.40M$500.00K$2.98M$23.05M$208.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$18.44M-$15.39M-$21.34M-$16.95M-$12.45M-$12.25M-$14.71M-$9.31M-$8.43M-$7.69M-$10.38M-$8.70M
    Capital expenditures$723.00K$332.00K$0$24.00K$4.00K$22.00K$44.00K$0$8.00K$55.00K$0$0
    Free cash flow-$19.16M-$15.72M-$21.34M-$16.97M-$12.46M-$12.27M-$14.76M-$9.31M-$8.44M-$7.74M-$10.38M-$8.70M
    Last 12 quarters

    Frequently Asked Questions About TARA

    What is Protara Therapeutics' annual revenue?

    Protara Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Protara Therapeutics profitable?

    No. Protara Therapeutics reported net income of -$57.44M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TARA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$56.37M minus capital expenditures of $94.00K produced free cash flow of -$56.46M.

    How much debt does Protara Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.24M and cash and equivalents of $49.66M.